-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67

Benzinga·11/05/2026 21:16:35
Listen to the news
Leerink Partners analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and lowers the price target from $78 to $67.